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Efficacy of Bezlotoxumab in Participants Receiving 
Metronidazole, Vancomycin, or Fidaxomicin for Treatment 
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Background. In phase 3 MODIFY I/II trials, bezlotoxumab significantly reduced recurrence of Clostridioides (Clostridium) 
difficile infection (rCDI) over 12 weeks. Choice of CDI antibacterial treatment may affect CDI-related outcomes; therefore, this 
prespecified analysis assessed if the magnitude of bezlotoxumab-induced rCDI reduction was influenced by the antibiotic 
administered.
Methods. In MODIFY I/II (NCT01241552/NCT01513239), participants received a single infusion of bezlotoxumab (10 mg/kg) 
or placebo during anti-CDI treatment. Using pooled data from MODIFY I/II, initial clinical cure (ICC) and rCDI were assessed in 
metronidazole-, vancomycin-, and fidaxomicin-treated subgroups.
Results. Of 1554 participants in MODIFY I/II, 753 (48.5%) received metronidazole, 745 (47.9%) vancomycin, and 56 (3.6%) 
fidaxomicin. Fewer participants receiving metronidazole had a prior CDI episode in the previous 6 months (12.9%) or ≥1 risk factor 
for rCDI (66.0%) vs participants receiving vancomycin (41.2% and 83.6%, respectively) and fidaxomicin (55.4% and 89.3%, respec-
tively). ICC rates were similar in the bezlotoxumab (metronidazole, 81.0%; vancomycin, 78.5%; fidaxomicin, 86.7%) and placebo 
groups (metronidazole, 81.3%; vancomycin, 79.6%; fidaxomicin, 76.9%). In placebo-treated participants, the rCDI was lower in the 
metronidazole subgroup vs the vancomycin and fidaxomicin subgroups (metronidazole, 28.0%; vancomycin, 38.4%; fidaxomicin, 
35.0%). When analyzed by subsets based on history of CDI, rCDI rates were similar in the metronidazole and vancomycin groups. 
rCDI rates were lower in all antibiotic subgroups for bezlotoxumab vs placebo (metronidazole: rate difference [RD], –9.7%; 95% 
confidence interval [CI], –16.4% to –3.1%; vancomycin: RD, –15.4%; 95% CI, –22.7% to –8.0%; fidaxomicin: RD, –11.9%; 95% CI, 
–38.1% to 14.3%).
Conclusion. Bezlotoxumab reduces rCDI vs placebo in participants receiving metronidazole and vancomycin, with a similar 
effect size in participants receiving fidaxomicin.
Keywords.  antibacterial drug treatment; bezlotoxumab; Clostridioides (Clostridium) difficile infection recurrence; toxin.
In recent years, Clostridioides (Clostridium) difficile has become 
one of the leading causes of hospital-acquired infections in 
the United States [1], with a marked increase in associated 
morbidity and mortality [2–4].
For 30 years, metronidazole and vancomycin were the main 
antibacterial drugs used in the treatment of C. difficile infection 
(CDI); metronidazole was recommended for mild to moderate 
CDI, whereas vancomycin was the preferred therapy for severe 
and recurrent infections [5]. However, studies have shown that 
vancomycin results in superior clinical cure rates compared with 
metronidazole in individuals with both nonsevere and severe 
CDI [6, 7]. Furthermore, treatment of an initial episode with 
fidaxomicin has been shown to significantly reduce the like-
lihood of recurrent CDI (rCDI) compared with vancomycin 
[8–10]. These findings have resulted in significant revisions to 
treatment guidelines, and in the 2017 Infectious Diseases Society 
of America/Society of Healthcare Epidemiology of America 
(IDSA/SHEA) CDI guidelines, the recommended first-line 
antibacterial drug treatment for severe and nonsevere CDI was 
vancomycin or fidaxomicin, rather than metronidazole [1].
Whereas antibiotic treatment of primary CDI is usually 
successful in decreasing signs and symptoms of the disease, 
it has been reported that ~25% of individuals will experience 
rCDI after initial antibiotic therapy [6, 10]. Treatment of rCDI 
remains challenging; following the first recurrent episode, 
individuals have a 38% probability of a second recurrence, 
despite initial episodes being treated with metronidazole or 
vancomycin [11]. The likelihood of additional recurrences is 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
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influenced by the choice of antibacterial drug treatment re-
ceived. In treating a first recurrent episode, fidaxomicin has 
been associated with a reduced rate of second recurrence 
compared with vancomycin [9].
Bezlotoxumab is a fully human monoclonal antibody against 
C.  difficile toxin B that is indicated to prevent the recurrence 
of rCDI in at-risk adults receiving antibacterial drug treat-
ment for CDI [12, 13]. MODIFY I/II were global, random-
ized, double-blind, placebo-controlled trials of the efficacy of 
bezlotoxumab for the prevention of rCDI in adults receiving 
metronidazole, vancomycin, or fidaxomicin. In the MODIFY 
trials, bezlotoxumab administered with or without actoxumab 
(a fully human monoclonal antibody against C.  difficile toxin 
A) was shown to significantly lower the rate of rCDI over 12 
weeks compared with placebo. The addition of actoxumab did 
not improve efficacy [14].
In the MODIFY trials, the selection of metronidazole, van-
comycin, or fidaxomicin to treat the presenting CDI episode 
was made by the treating physician [14]. The 2010 IDSA/SHEA 
CDI guidelines, which were in effect at the time of study enroll-
ment, recommended metronidazole for the treatment of mild/
moderate CDI and vancomycin for severe CDI and multiple 
rCDI [5]. Fidaxomicin was not included in the 2010 guidelines 
because it was approved in 2011 [15]. Fidaxomicin became 
available shortly before initiation of the MODIFY trials, and as 
it is indicated for treatment of CDI, it was allowed as an anti-
biotic choice for these trials. As the rate of rCDI could be in-
fluenced by the antibacterial drug treatment received for the 
presenting CDI episode, treatment groups were stratified at the 
time of randomization according to this variable in both trials.
Given the potential influence of the antibacterial drug 
treatment received on rCDI, this prespecified analysis exam-
ined if the administration of metronidazole, vancomycin, or 
fidaxomicin had an impact on efficacy outcomes in participants 
receiving bezlotoxumab or placebo in the MODIFY I/II trials.
METHODS
Study Design
MODIFY I (NCT01241552) and MODIFY II (NCT01513239) 
were randomized, double-blind, placebo-controlled, 
multicenter, phase 3 trials conducted between November 1, 
2011, and May 22, 2015, at 322 sites in 30 countries. Full details 
of the trials have been published previously [14]. Briefly, partici-
pants receiving metronidazole, vancomycin, or fidaxomicin for 
primary or rCDI were randomized in a 1:1:1:1 ratio to receive a 
single infusion of actoxumab plus bezlotoxumab (10 mg/kg of 
body weight each), bezlotoxumab alone (10 mg/kg), actoxumab 
alone (10 mg/kg; MODIFY I only), or placebo (0.9% saline).
Antibacterial drug treatment for the presenting CDI episode 
was to be administered for a minimum of 10  days and a 
maximum of 14  days in an attempt to control any influence 
of treatment duration on CDI-related outcomes. Initial clin-
ical cure (ICC) was imputed as failure if treatment was given 
longer than 14 days (defined as 16 calendar days to account for 
partial dosing on the first and last days). Choice of antibacte-
rial treatment for CDI was per the treating clinician’s discre-
tion and could not be changed during the MODIFY I/II trials. 
Randomization was stratified according to oral antibacterial 
drug treatment (metronidazole, vancomycin, or fidaxomicin) 
and hospitalization status (inpatient or outpatient) at the time 
of study randomization.
MODIFY I/II were conducted in accordance with Good 
Clinical Practice guidelines and the provisions of the Declaration 
of Helsinki. The protocols and amendments were approved by 
the institutional review board or independent ethics committee 
at each study site. Written informed consent was provided by all 
participants before entering the trial.
Prespecified Analysis of Pooled Data From MODIFY I/II
In this prespecified analysis of pooled data from the MODIFY 
I/II trials, which includes only participants who received 
bezlotoxumab alone or placebo, efficacy end points were 
assessed based on the antibacterial drug administered to treat 
the presenting CDI episode. The metronidazole, vancomycin, 
and fidaxomicin subgroups were based on the antibacterial 
drug that was entered by the investigator into the randomiza-
tion system (ie, the stratification factor). In a few instances (62 
participants of 1554 [4%] included in the modified intent-to-
treat [mITT] population), the stratification factor differed from 
the antibacterial drug that the participant ultimately received. 
The results reported here are based on the stratification factor 
to be consistent with the original statistical analysis plan.
Efficacy End Points and Statistical Methods
The primary end point was rCDI, which was defined as a new 
episode of diarrhea (≥3 unformed stools in 24 hours) associ-
ated with a positive stool test for toxigenic C. difficile within 12 
weeks of bezlotoxumab or placebo infusion in participants who 
had achieved ICC of the baseline CDI episode (clinical cure 
population). ICC was an exploratory end point, which was de-
fined as no diarrhea during the 2 consecutive days after com-
pletion of ≤14  days of antibacterial drug treatment. Rates of 
all-cause 30-day and 90-day mortality were estimated in the all-
patients-as-treated (APaT) population. The rates of all-cause 
and CDI-related rehospitalization within 30 days of antibiotic 
treatment were assessed in participants who were inpatients at 
the time of randomization. An additional analysis using only 
data from placebo participants is presented here. This analysis 
explores the impact of a confounding variable (prior history 
of CDI) on the assessment of rCDI in each of the antibacterial 
drug cohorts.
The analysis population for ICC was the mITT population, 
which included all randomized participants in the overall 
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population of the MODIFY I/II trials who received the study in-
fusion, had a positive baseline stool test for toxigenic C. difficile, 
and initiated antibacterial drug treatment before, or within 
1 day after, the study infusion [14].
Observed rates of ICC and rCDI are presented, along 
with rate differences between the bezlotoxumab and placebo 
groups and their 95% confidence intervals (CIs). The 95% CIs 
are based on the Miettinen and Nurminen method without 
stratification [16].
RESULTS
Participants
The integrated mITT population from MODIFY I/II consisted 
of 1554 participants, of whom 781 received bezlotoxumab and 
773 received placebo. The majority of participants received 
oral metronidazole or oral vancomycin. Across both treatment 
groups, 753 (48.5%) participants were in the metronidazole 
stratum, 745 (47.9%) were in the vancomycin stratum, and 56 
(3.6%) were in the fidaxomicin stratum. By design, the propor-
tions of participants receiving bezlotoxumab and placebo were 
similar in each antibacterial drug treatment subgroup (Table 1).
The mean number of calendar days of antibacterial treat-
ment before infusion with the study agent was similar between 
subgroups (metronidazole, 3.3  days; vancomycin, 3.2  days; 
fidaxomicin, 3.0  days), as was the mean total duration of 
antibacterial treatment (metronidazole, 13.6 days; vancomycin, 
14.5  days; fidaxomicin, 11.9  days). Across all subgroups, the 
number of days on antibacterial treatment before infusion 
ranged from 0 to 14  days and the total number of treatment 
days ranged from 2 to 87 days. (Table 1).
Although many participant characteristics were gener-
ally similar between the metronidazole, vancomycin, and 
fidaxomicin subgroups, there were some notable differences. 
Compared with participants who received metronidazole, parti-
cipants who received vancomycin were of an older age (median 
age [range], 62 [49–75] years vs 67 [56–78] years; ≥65  years: 
45.6% vs 57.1%), more likely to have ≥1 episode of CDI in the 
past 6 months (12.9% vs 41.2%), more likely to have ≥1 prede-
fined risk factor for rCDI (66.0% vs 83.6%), more likely to be 
an inpatient at the time of infusion (64.8% vs 71.7%), and more 
likely to have severe disease at baseline (Zar Score ≥2: 13.3% vs 
18.7%) (Table 2). Compared with the metronidazole and van-
comycin subgroups, participants in the fidaxomicin subgroup 
were more likely to have ≥1 episode of CDI ever (metronida-
zole, 16.9%; vancomycin, 46.0%; fidaxomicin, 69.6%). Notably, 
21.4% of participants in the fidaxomicin subgroup had ≥3 prior 
CDI episodes, compared with 2.3% and 9.1% of metronidazole- 
and vancomycin-treated participants, respectively (Table 2).
Initial Clinical Cure
ICC rates were similar across antibiotic strata in the placebo group 
(metronidazole, 81.3%; vancomycin, 79.6%; fidaxomicin, 76.9%) 
and the bezlotoxumab group (metronidazole, 81.0%; vancomycin, 
78.5%; fidaxomicin, 86.7%). There was no difference in ICC 
rates between participants receiving bezlotoxumab and placebo, 
regardless of whether metronidazole, vancomycin, or fidaxomicin 
was administered to treat the presenting CDI episode (metro-
nidazole: rate difference [RD], –0.3%; 95% CI, –5.9% to 5.3%; 
Table 1. Administered Antibacterial Drug Treatment for CDI According to 
Treatment Group (mITT Population)
Bezlotoxumab  
(N = 781), n (%)
Placebo  
(N = 773), n (%)
Metronidazole stratum 
(48.5% of participants)
379 374
 Oral metronidazole alone 361 (95.3) 344 (92.0)
 Oral metronidazole with IV 
metronidazole
7 (1.8) 2 (0.5)
 Othera 11 (2.9) 28 (7.5)
 Days on antibacterial 
treatment before infusionb
  
  Mean (SD) 3.4 (2.1) 3.1 (2.1)
  Median (range) 3 (0 to 13) 3 (0 to 11)
 Total days on antibacterial 
treatmentb,c
  
  Mean (SD) 13.4 (3.5) 13.7 (4.9)
  Median (range) 14 (2 to 37) 13 (5 to 62)
Vancomycin stratum  
(47.6% of participants)
372 373
 Oral vancomycin alone 318 (85.5) 300 (80.4)
 Oral vancomycin with 
IV metronidazole
44 (11.8) 52 (13.9)
 Othera 10 (2.7) 21 (5.6)
 Days on antibacterial 
treatment before infusionb
  
  Mean (SD) 3.2 (2.2) 3.3 (2.1)
  Median (range) 3 (0 to 14) 3 (–1 to 13)
 Total days on antibacterial 
treatmentb,c
  
  Mean (SD) 14.7 (7.7) 14.3 (5.1)
  Median (range) 14 (4 to 87) 14 (3 to 67)
Fidaxomicin stratum  
(3.8% of participants)
30 26
 Oral fidaxomicin alone 26 (86.7) 24 (92.3)
 Oral fidaxomicin with IV 
metronidazole
1 (3.3) 1 (3.8)
 Othera 3 (10.0) 1 (3.8)
 Days on antibacterial 
treatment before infusionb
  
  Mean (SD) 3.0 (2.9) 3.0 (2.2)
  Median (range) 2 (0 to 12) 3 (0 to 8)
 Total days on antibacterial 
treatmentb,c
  
  Mean (SD) 11.8 (2.3) 12.0 (2.3)
  Median (range) 11 (10 to 20) 11 (10 to 21)
Abbreviations: CDI, Clostridioides difficile infection; IV, intravenous; mITT, modified 
intent-to-treat.
aThe actual antibacterial drug treatment for CDI on the day of infusion differed from the 
stratification antibacterial drug treatment for CDI.
bData represent the number of calendar days.
cData for total days on antibacterial treatment reflect the days on therapy for all antibiotics 
given to treat the CDI episode under treatment at the time of randomization and include 
days before, the day of, and days after administration of study medication.
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vancomycin: RD, –1.1%; 95% CI, –7.0% to 4.7%; fidaxomicin: 
RD, 9.7%; 95% CI, –11.0% to 31.3%). Similar ICC rates were also 
observed in the overall study results, with no difference in the 
rate between bezlotoxumab-treated (80.0%) and placebo-treated 
participants (80.3%; RD, –0.3%; 95% CI, –4.3% to 3.7%) (Figure 1).
CDI Recurrence
Differences Between Antibacterial Treatment Subgroups
In placebo-treated participants, 28.0% of participants in the 
metronidazole subgroup experienced rCDI compared with 
38.4% of participants in the vancomycin subgroup (RD, 10.4%; 
95% CI, 2.9% to 17.9%) (Figure 2). However, the difference in 
rCDI rate between antibacterial treatment groups decreased 
when patients were stratified by history of CDI: in participants 
with primary CDI, 25.5% of metronidazole-treated participants 
experienced rCDI compared with 27.8% of vancomycin-treated 
participants (RD, 2.4%); in participants with ≥1 episode of CDI 
in the past 6 months, 46.2% of metronidazole-treated partici-
pants experienced rCDI compared with 50.4% of vancomycin-
treated participants (RD, 4.2%). Following adjustment for prior 
CDI history, the overall difference (vancomycin minus metro-
nidazole) in the proportion of participants who experienced 
rCDI (among those with ICC) was 2.8% (95% CI, –5.0% to 
10.8%). The relationship between CDI history in the previous 
6  months and occurrence of rCDI in placebo-treated partici-
pants with ICC is presented in Figure 3. As plots for metroni-
dazole and vancomycin fall to the trend line, this suggests that 
the difference in the observed rCDI rates between these sub-
groups is largely explained by a baseline difference between the 
2 cohorts.
Differences Between Bezlotoxumab and Placebo Within 
Antibacterial Treatment Subgroups
In the metronidazole and vancomycin subgroups, participants 
who received bezlotoxumab experienced a significantly lower rate 
of rCDI compared with placebo (metronidazole: RD, –9.7%; 95% 
CI, –16.4% to –3.1%; vancomycin: RD, –15.4%; 95% CI, –22.7% to 
–8.0%). In the fidaxomicin subgroup, there was a trend for a reduc-
tion in rCDI rate in bezlotoxumab-treated participants compared 
with placebo (RD, –11.9%; 95% CI, –38.1% to 14.3%) (Figure 2).
Other Outcomes
All-cause and CDI-related rehospitalization was similar across 
antibiotic treatment subgroups for placebo-treated participants, 
but there was a higher rate of CDI-associated readmissions 
in vancomycin-treated participants (vancomycin, 14.0%; 
metronidazole, 8.3%; fidaxomicin, 7.7%) (Table 3). CDI-related 
rehospitalizations were lower for bezlotoxumab compared with 
placebo in the metronidazole (4.9% vs 8.3%) and vancomycin 
subgroups (5.2% vs 14.0%) (Table  3). Mortality rates were 
similar regardless of antibiotic treatment or bezlotoxumab 
administration (Table 3).
DISCUSSION
rCDI remains a central unmet need in the management of CDI, 
with no uniformly effective treatment approach. Following 
significant revisions to treatment guidelines, vancomycin and 
fidaxomicin are the recommended antibacterial drugs for the 
treatment of CDI [1]. However, studies have demonstrated 
that the choice of antibacterial drug treatment may affect the 
likelihood of further rCDI episodes [8–10]. In MODIFY I/II, 
bezlotoxumab was shown to substantially reduce the rate of 
Table 2. Baseline Demographics and Clinical Characteristics in 
Treatment Groups (mITT Population)
Metronidazole 
Stratum  
(N = 753), n (%)
Vancomycin 
Stratum  
(N = 745), 
n (%)
Fidaxomicin  
Stratum  
(N = 56), n (%)
Age, years    
Mean (SD) 60.6 (18.4) 64.9 (16.8) 61.3 (18.4)
Median (IQR) 62 (49–75) 67 (56–78) 63 (54–72)
 ≥65 years 343 (45.6) 426 (57.2) 26 (46.4)
 ≥75 years 194 (25.8) 244 (32.7) 10 (17.9)
Female 433 (57.5) 422 (56.6) 36 (64.3)
Inpatient at the time  
of randomization
488 (64.8) 534 (71.7) 28 (50.0)
Immunocompromiseda 165 (21.9) 155 (20.8) 11 (19.6)
≥1 of 5 predefined  
risk factors for rCDIb
497 (66.0) 623 (83.6) 50 (89.3)
Charlson Comorbidity 
Index ≥3 
304 (40.4) 288 (38.7) 30 (53.6)
Renal impairmentc 113 (15.0) 113 (15.2) 7 (12.5)
Hepatic impairmentd 43 (5.7) 47 (6.3) 3 (5.4)
≥1 CDI episodes in past 
6 months
97 (12.9) 307 (41.2) 31 (55.4)
≥1 CDI episode ever 127 (16.9) 342 (45.9) 39 (69.6)
Number of prior CDI 
episodes
   
 0 613 (81.4) 388 (52.1) 17 (30.4)
 1 93 (12.4) 178 (23.9) 11 (19.6)
 2 17 (2.3) 96 (12.9) 16 (28.6)
 ≥3 17 (2.3) 68 (9.1) 12 (21.4)
Severe CDI 
(Zar Scoree  ≥2)
100 (13.3) 139 (18.7) 8 (14.3)
Participants with a  
positive culture
517 (68.7) 431 (57.9) 28 (50.0)
Ribotype 027, 078, 
or 244
89 (11.8) 121 (16.2) 7 (12.5)
Ribotype 027 72 (9.6) 111 (14.9) 6 (10.7)
Abbreviations: ALT, alanine aminotransferase; CDI, Clostridioides difficile infection; IQR, 
interquartile range; mITT, modified intent-to-treat; rCDI, recurrent C. difficile infection; ULN, 
upper limit of normal; WBC, white blood cell.
aDefined as the basis of a participant’s medical history or use of immunosuppressive therapy.
bPredefined risk factors include CDI history in the past 6 months, severe CDI at baseline 
(per Zar score), age ≥65 years, having a hypervirulent strain (027, 078, or 244 ribotypes) at 
baseline, and being immunocompromised.
cSerum creatinine ≥1.5 mg/dL.
dBased on 2 or more of the following: (1) albumin ≤3.1 g/dL; (2) ALT ≥2X ULN; (3) total 
bilirubin ≥1.3X ULN; or (4) mild, moderate, or severe liver disease (as reported on the 
Charlson comorbidity index).
eBased on the following: (1) age >60 years (1 point); (2) body temperature >38.3˚C (>100˚F; 
1 point); (3) albumin level <2.5 mg/dL (1 point); (4) peripheral WBC count >15 000 cells/
mm3 within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 
points); and (6) treatment in intensive care unit (2 points).
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rCDI in participants receiving metronidazole, vancomycin, or 
fidaxomicin over 12 weeks compared with placebo [14].
Here, we show that the majority of participants in MODIFY 
I/II received oral metronidazole or oral vancomycin, which is 
consistent with the treatment guidelines that were in effect at the 
time of study enrollment [5]. We also demonstrate that the rate of 
ICC was ~80% in participants who received placebo, regardless 
of whether metronidazole, vancomycin, or fidaxomicin was ad-
ministered. A  single infusion of bezlotoxumab did not affect 
ICC rates with any antibacterial drug.
In participants receiving a placebo infusion, the rate of rCDI 
was lowest in the metronidazole subgroup compared with the 
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Figure 1. Proportion of participants with initial clinical cure (mITT population). aBased on the Miettinen and Nurminen method. Abbreviations: CDI, Clostridioides difficile 
infection; CI, confidence interval, mITT, modified intent-to-treat.
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CI, confidence interval; rCDI, recurrent C. difficile infection.
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vancomycin or fidaxomicin subgroups. However, this is likely 
explained by some notable differences in participant charac-
teristics between antibacterial subgroups; compared with par-
ticipants in the metronidazole subgroup, participants in the 
vancomycin subgroup were more likely to be older, have a 
history of CDI, have ≥1 predefined risk factor for rCDI, be an 
inpatient, or have severe CDI disease at baseline. Participants in 
the fidaxomicin subgroup were more likely to have ≥1 episode of 
CDI ever, and a higher proportion of participants had ≥3 prior 
CDI episodes compared with those who received metronidazole 
or vancomycin. These findings suggest a selection bias toward 
metronidazole treatment in lower-risk participants and vanco-
mycin or fidaxomicin treatment in higher-risk participants, thus 
explaining the lower rate of rCDI in participants treated with 
metronidazole.
Results from logistic regression models based on placebo 
data from these trials, which have been published elsewhere, 
demonstrated that the choice of antibacterial drug treatment 
Table 3. Proportion of Participants With 30-Day Rehospitalization and All-Cause Mortality by Treatment Arm and Antibacterial Subgroups
Bezlotoxumab Placebo
 Metronidazole Vancomycin Fidaxomicin Metronidazole Vancomycin Fidaxomicin
30-day rehospitalizations,  
% (n/N)
      
 All-cause 22.0  
(n = 54/246)
22.7  
(n = 61/269)
53.3  
(n = 8/15)
25.6  
(n = 62/242)
27.9  
(n = 74/265)
30.8  
(n = 4/13)
 CDI-related 4.9  
(n = 12/246)
5.2  
(n = 14/269)
6.7  
(n = 1/15)
8.3  
(n = 20/242)
14.0  
(n = 37/265)
7.7  
(n = 1/13)
Mortality, % (n/N)       
 30-day 4.0  
(n = 15/377)
3.2  
(n = 12/380)
0.0  
(n = 0/29)
4.2  
(n = 16/380)
2.7  
(n = 10/374)
3.7  
(n = 1/27)
 90-day 7.4  
(n = 28/377)
6.3  
(n = 24/380)
6.9  
(n = 2/29)
8.4  
(n = 32/380)
6.7  
(n = 25/374)
7.4  
(n = 2/27)
Abbreviation: CDI, Clostridioides difficile infection.
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Figure 3. Relationship between CDI history in the previous 6 months and occurrence of rCDI in placebo-treated participants receiving metronidazole or vancomycin. 
The relationship between CDI history in the previous 6 months and occurrence of rCDI in placebo-treated participants with ICC (n = 621) is represented by the dotted 
trend line. The difference in the percentage of participants in the metronidazole and vancomycin subgroups with a history of CDI in the previous 6 months is represented 
by the distance between the black (metronidazole) and gray (vancomycin) reference lines. Abbreviations: CDI, Clostridioides difficile infection; ICC, initial clinical cure; 
rCDI, recurrent C. difficile infection.
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for CDI was not predictive of rCDI; however, a history of CDI 
in the previous 6  months was associated with increased risk 
[17, 18]. To further explore the apparent difference in rCDI 
between antibacterial treatment subgroups, an analysis of rCDI 
that stratified according to history of CDI was conducted and 
demonstrated similar rCDI rates between the metronidazole 
and vancomycin subgroups. These results are in agreement with 
previous studies, which also reported similar rCDI rates for 
metronidazole and vancomycin, although the clinical success 
(defined as resolution of diarrhea and absence of severe abdom-
inal discomfort for >2 consecutive days including day 10)  of 
metronidazole was reported as inferior to vancomycin for par-
ticipants with severe CDI [6].
In this analysis, few participants were rehospitalized due to 
CDI within 30 days of antibiotic infusion; however, CDI-related 
readmissions were numerically higher for placebo-treated par-
ticipants compared with bezlotoxumab. The proportions of par-
ticipants who died within 30 and 90 days of antibiotic infusion 
were similar across all subgroups.
Our study demonstrates that in participants who received 
metronidazole or vancomycin to treat the presenting CDI epi-
sode, bezlotoxumab was associated with statistically significant 
and clinically meaningful reductions in rates of rCDI compared 
with placebo (35% and 40% relative reductions, respectively). In 
participants who received fidaxomicin, the bezlotoxumab rela-
tive recurrence reduction was 34% but did not meet statistical 
significance, which was likely due to a small number of parti-
cipants in the fidaxomicin subgroup. As the administration of 
metronidazole, vancomycin, or fidaxomicin was determined by 
the treating physician, this large, pooled data set provides real-
world evidence of the efficacy of bezlotoxumab in individuals 
receiving these antibacterial drugs.
The limitations of the study include the small sample size 
in the fidaxomicin subgroup. In addition, as the study was not 
designed to compare the efficacy of different antibacterial drugs, 
the comparisons are confounded by differences in participant 
baseline characteristics associated with rCDI and CDI severity. 
As a result, comparisons of the outcomes in the placebo group 
by antibacterial therapy should not be considered conclusive.
CONCLUSIONS
Participants in the MODIFY I/II trials who received 
bezlotoxumab with vancomycin or metronidazole demon-
strated a significantly lower rate of rCDI compared with 
antibiotic treatment alone. A  similar effect size for reduction 
in the rate of rCDI was observed for participants who received 
bezlotoxumab with fidaxomicin.
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